• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Novel hybrid closed-loop system improves glycemic control in young adults with type 1 diabetes

byConstance Wu
February 3, 2021
in StudyGraphics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Participants using the novel advanced hybrid insulin delivery system (Medtronic) had a greater proportion of time spent in their target glucose range versus control.

2. Proportion of time spent in hypoglycemic ranges was non-inferior between the Medtronic and control groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Although various technological advances have improved the management of Type 1 Diabetes, proper monitoring of blood sugar and insulin administration remains a constant challenge. More recent devices in the USA, such as the MiniMed 670G, are hybrid closed-loop systems that use automated insulin delivery to improve blood sugar management; however, studies have shown that even with this, patients can miss their target glucose range by as much as 30% of the time. The novel advanced hybrid closed-loop system, the Medtronic system, seeks to improve this shortcoming using advanced algorithms and monitoring. This open-label, randomized crossover trial sought to compare the commercially available MiniMed 670G system with the novel Medtronic device in young adults with type 1 diabetes. Overall, participants using the Medtronic device had a greater proportion of time spent in their target blood glucose range over a 24h period. They also demonstrated moderately lower levels of HbA1c over this period. Participants also reported a higher rating of satisfaction with the use of the Medtronic device. Overall, this study provides strong evidence for the use of the new Medtronic device. Its use of a crossover design, with benefits for the new device evident in both groups, is a particular strong point. However, a notable limitation is the short study duration (3 months), as it is well known that blood glucose management can fluctuate significantly over the course of months or years for diabetics.

Click to read the study in The Lancet

Relevant Reading: Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes.

In-Depth [randomized controlled trial]: This open-label, randomized crossover trial occurred at seven institutions across the USA, Germany, Israel and Slovenia. Eligible participants were young adults aged 14-29 years with type 1 diabetes on insulin pump or multiple daily injections. Over a total of two periods of 12 weeks, participants were randomly assigned to either the MiniMed or Medtronic group, and then crossed over to utilize the other device. The coprimary outcomes of this study were proportion of time spent with glucose levels over 180 mg/dL between daytime hours of 06:00-23:59h, as well as proportion of time spent with glucose levels below 54 mg/dL in a 24h period. A total of 113 participants were randomized into the two crossover groups; 56 began with the Medtronic and 57 with the MiniMed system, respectively. Average proportion of time with glucose levels >180 mg/dL between 06:00-23:59h was lower in the novel Medtronic group (34% vs 37%; mean difference = -3.00% [95% CI -3.96 to 2.04]; p<0.0001 for superiority). Additionally, average proportion of time with glucose levels <54 mg/dL over 24h was lower during Medtronic device use (0.46% vs 0.50%; mean difference= -0.06% [95% CI -0.11% to -0.02%]; p<0.0001 for non-inferiority). Overall, participants in the Medtronic group spent more time in the target glucose range of 70-180 mg/dL (67% Medtronic vs. 63% MiniMed) and had lower mean HbA1c levels (7.4% Medtronic vs. 7.6% MiniMed, p=0.026).

RELATED REPORTS

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: closed loopdiabeteshyperglycemiahypoglycemiamedtronict1dmtype 1 diabetesType 1 Diabetes Mellitus
Previous Post

Adavosertib plus gemcitabine improves survival in platinum-resistant recurrent ovarian cancer

Next Post

Alcohol consumption and risk of cardiovascular outcomes and bleeding in patients with established atrial fibrillation

RelatedReports

Type 2 diabetes associated with reduction in disability-free life years
Chronic Disease

Metformin use in Type 2 Diabetes associated with decreased risk of joint replacement

January 16, 2023
Pediatric DKA associated with recent acute care visits
Cardiology

Low-carbohydrate, high-fat diet improves glycemic control in type 2 diabetic patients

January 11, 2023
Cardiology

Diabetes is a risk factor for high platelet reactivity post percutaneous coronary intervention

December 26, 2022
Solitary kidney not associated with contrast-induced nephropathy
Chronic Disease

Dapagliflozin reduces the risk of hospitalization in patients with chronic kidney disease

December 26, 2022
Next Post
Greater prenatal alcohol exposure trajectories linked to impaired growth and neurodevelopment

Alcohol consumption and risk of cardiovascular outcomes and bleeding in patients with established atrial fibrillation

Fatty liver disease may independently predict high-risk coronary disease

Liver fibrosis in post-PCI patients associated with higher incidence of cardiovascular events

#VisualAbstract: Fixed-dose, subcutaneous injection of pertuzumab and trastuzumab is noninferior to intravenous administration in HER2⁺ breast cancer

#VisualAbstract: Fixed-dose, subcutaneous injection of pertuzumab and trastuzumab is noninferior to intravenous administration in HER2⁺ breast cancer

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • BNT162b2 booster is safe and reduces COVID-19 transmission in older adults
  • Bisphosphonates, denosumab, abaloparatide, teriparatide, and romosozumab reduce postmenopausal fracture risk
  • Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options